|
February 13, 2012
|
| 08:02 EDT |  | BDX |
|
| 08:02 EDT |  | BDX |
|
|
February 8, 2012
|
| 09:07 EDT | | BDX |
|
|
February 7, 2012
|
| 10:33 EDT |  | BDX |
| theflyonthewall.com: | Argus Research's healthcare analyst holds a conference call | | Senior Healthcare Analyst Toung discusses healthcare and growth ideas for 2012 on an Analyst/Industry conference call. Relevant covered companies ABC, ABT, AET, BAX, BDX, BSX, CAH, CHSI, CI, ESRX, HMA, HOLX, HUM, IART, JNJ, MCK, MDT, MHS, STJ, SYK, UNH and ZMH may be included on the Analyst/Industry conference call to be held on February 8 at 11 am. :theflyonthewall.com |
|
| 09:13 EDT |  | BDX |
|
| 08:46 EDT | | BDX |
| theflyonthewall.com: | Becton Dickinson repurchased ~$400M in stock in Q1 | | :theflyonthewall.com |
|
| 08:24 EDT | | BDX |
|
| 08:23 EDT | | BDX |
|
| 08:16 EDT | | BDX |
|
| 07:55 EDT | | BDX |
|
| 06:14 EDT | | BDX |
|
| 06:08 EDT | | BDX |
|
| 06:06 EDT | | BDX |
| theflyonthewall.com: | Becton Dickinson cuts FY12 cont ops EPS to $5.60-$5.70 vs. consensus $5.80 | | The company had seen FY12 continuing operations EPS of $5.75-$5.85. Cites impact of a strengthening US dollar. :theflyonthewall.com |
|
| 06:04 EDT | | BDX |
| theflyonthewall.com: | Becton Dickinson reports Q1 EPS $1.21 vs. consensus $1.17 | | Reports Q1 revenue $1.89B vs. consensus $1.88B :theflyonthewall.com |
|
|
February 6, 2012
|
| 15:46 EDT | | BDX |
| theflyonthewall.com: | Companies reporting Before the Market Open on Tuesday, February 07 | | Notable companies reporting before the opening bell on Tuesday include Becton Dickinson (BDX), Coca-Cola (KO), Emerson Electric (EMR), Harman International (HAR) and Perrigo (PRGO). :theflyonthewall.com |
|
| 08:33 EDT | | BDX |
| theflyonthewall.com: | SDIX announces collaboration with BD Diagnostics | | SDIX (SDIX), a leading provider of biotechnology-based products and services for a broad range of life science, biotechnology, diagnostic and food safety applications, and BD Diagnostics, a segment of BD (BDX), announced the signing of a comprehensive agreement whereby the two companies will collaborate in the development of a microbiology detection solution. Under the agreement, SDIX will provide BD Diagnostics access to its proven antibody technology and a non-exclusive license to its patented bacteria phage technology. BD will pay SDIX a $1.25M upfront fee for a combination of license fees, technology access fees, and paid-for research during system development. In addition to the upfront payment, the agreement provides up to $2.5M in milestone payments and royalties on product sales incorporating SDIX’s patented technology. :theflyonthewall.com |
|
|
February 3, 2012
|
| 07:39 EDT |  | BDX |
|
|
February 2, 2012
|
| 14:05 EDT | | BDX |
| theflyonthewall.com: | FDA and industry reach agreement in principle on medical device user fees | | The FDA and representatives from the medical device industry have reached an agreement in principle on proposed recommendations for the third reauthorization of a medical device user fee program. The recommendations would authorize the FDA to collect $595M in user fees over five years, plus adjustments for inflation. Details of the agreement, such as the fee structure, are expected to be finalized soon. :theflyonthewall.com |
|
|
February 1, 2012
|
| 10:33 EDT |  | BDX |
|
| 06:17 EDT | | BDX |
|
Subscribe for More Information